# Ipamorelin Research: Mechanism, Bone Data, PK, and the Failed Human Trial > Ipamorelin research: GHS-R1a mechanism, bone-skeletal preclinical data, ~2 h human half-life, and the Phase 2 ileus trial that missed. Every claim cited. Mechanism, bone-skeletal data, pharmacokinetics, the human trial, and how it differs from the GHRH analogs it gets paired with. ## The short version Ipamorelin research is mostly animal work, anchored by one human trial that did not work and one that just measured the basics. The core finding repeats across studies: ipamorelin releases a clean pulse of growth hormone through the ghrelin receptor, without dragging up cortisol or prolactin. (Ghrelin receptor = the docking site the body's hunger hormone uses; cortisol = the stress hormone; prolactin = a pituitary hormone.) The bone-skeletal data is the strongest preclinical thread: longer bones, more bone mineral, partial rescue of steroid-damaged bone — all in rats. The human file is two studies: a failed Phase 2 trial after bowel surgery, and a pharmacokinetic study that pinned the half-life near 2 hours. Below: mechanism, bone, pharmacokinetics, the human data, and how ipamorelin sits next to CJC-1295, sermorelin, and tesamorelin. ## Mechanism: one receptor, a clean pulse Ipamorelin activates GHS-R1a — the growth hormone secretagogue receptor, also the ghrelin receptor — on the pituitary's somatotrophs (its growth-hormone-making cells). That triggers a Gq/phospholipase-C cascade, a rise in intracellular calcium, and a pulse of growth hormone [4]. The defining result: potent growth-hormone release with no meaningful ACTH or cortisol rise, even past 200-fold the growth-hormone ED50, in rats and pigs [4]. Pig ED50 was 2.3 nmol/kg versus 3.9 nmol/kg for GHRP-6 [4]. The receptor mechanism is conserved far down the tree — in fish pituitary cells, ipamorelin released growth hormone without changing growth-hormone gene transcription, placing the action at secretion, not gene expression [11]. The growth-hormone pathway is distinct from and complementary to GHRH, which is the entire reason ipamorelin gets paired with GHRH analogs. ## Bone and skeletal data This is the lens this digest leads with. Three rat studies carry it. Longitudinal growth: ipamorelin at 18, 90, and 450 microg/day SC (15 days) raised the bone growth rate from 42 to 44, 50, and 52 microm/day, dose-dependently, with no change in total IGF-1 or bone turnover markers — a partly local, growth-hormone-pulse-driven skeletal effect [1]. Bone mineral content: 0.5 mg/kg/day continuous SC for 12 weeks raised tibial and vertebral bone mineral content by DXA, while cortical volumetric density stayed flat — growth by bone dimension, not density [2]. Glucocorticoid rescue: 100 microg/kg three times daily for 3 months, with a steroid, raised the periosteal bone formation rate roughly four-fold versus steroid alone and lifted maximum tetanic muscle tension [3]. One supporting study confirms the growth-hormone response survives steroid load: methylprednisolone did not blunt ipamorelin's acute growth-hormone release, and the combination raised IGF-1 and recovered body weight [9]. Real, reproducible — and entirely preclinical. ## Pharmacokinetics and routes Human pharmacokinetics come from one study: eight healthy men per dose level, five IV infusions of 4.21-140.45 nmol/kg over 15 minutes. Kinetics were dose-proportional — terminal half-life about 2 hours, clearance 0.078 L/h/kg, steady-state volume of distribution 0.22 L/kg — and the growth-hormone response was a single pulse peaking near 40 minutes [6]. Routes studied: intravenous (human and rodent), subcutaneous (the rodent bone studies and the dominant community route), intranasal (rat, ~20% bioavailability), and intraperitoneal (rodent and ferret). Ipamorelin itself is not orally bioavailable; only engineered analogs are. In rats, plasma clearance ran roughly 5-fold lower than GHRP-6 [4]. ## Recent research (2024-2026) The freshest in vivo study is a 2024 ferret experiment. Intraperitoneal ipamorelin (1-3 mg/kg) cut cisplatin-induced body-weight loss by about 24% on the last day of the delayed phase, but had no anti-emetic effect — in contrast to central anamorelin, which reduced acute vomiting by 60% [14]. Reduced chemotherapy-associated weight loss through a peripheral mechanism, no anti-nausea action. A 2026 orthopaedic and sports-medicine narrative review reports that CJC-1295 combined with ipamorelin improved maximum tetanic muscle tension in a glucocorticoid-induced muscle-loss model in mice, while stressing that the evidence is limited to animal studies [15]. ## Ipamorelin cjc-1295 The ipamorelin cjc-1295 pairing is the most common community protocol, and its logic is two-pathway. Ipamorelin is a ghrelin-receptor agonist that fires a pulse; CJC-1295 is a long-acting GHRH analog that raises the baseline. In healthy adults, CJC-1295 produced dose-dependent 2- to 10-fold growth-hormone increases for 6+ days and 1.5- to 3-fold sustained IGF-1 elevation after a single subcutaneous dose, while preserving pulsatile secretion [12] — that study is on CJC-1295, not ipamorelin. Pairing a steady GHRH analog with a pulsatile GHRP is the rationale. No controlled trial has tested the combination itself for any outcome. ## What is cjc 1295 ipamorelin Cjc 1295 ipamorelin is a two-peptide pairing, not a single drug. CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH); ipamorelin is a selective ghrelin-receptor agonist. They act on different receptors — the GHRH receptor and GHS-R1a — and the published rationale is that the two pathways are complementary [4][12]. The evidence for each agent is single-agent: there is no trial of the combined product. Everything written about the pair as a unit is extrapolation from the two separate files. ## Does cjc-1295 ipamorelin work For raising growth hormone in the short term, the single-agent evidence is real: CJC-1295 raised growth hormone and IGF-1 for days in healthy adults [12], and ipamorelin reliably pulses growth hormone across species [4]. For the outcomes people actually want — fat loss, muscle, anti-aging — there is no controlled human trial of the combination, and the strongest combination data is a mouse muscle-loss model reported in a 2026 review [15]. So: the hormones move; the human outcomes are unproven [12][4][15]. ## Ipamorelin vs sermorelin Different receptors, different jobs. Sermorelin is a GHRH (1-29) analog — it works on the GHRH receptor to raise baseline growth-hormone output and has an approved pharmaceutical history. Ipamorelin works on the ghrelin receptor (GHS-R1a) to fire a discrete pulse and was never approved [4]. Sermorelin's appeal is being a short GHRH fragment; ipamorelin's is selectivity — growth hormone without cortisol or prolactin [4]. In community stacks they are sometimes used the way CJC-1295 is: a GHRH-side agent paired with the GHRP-side ipamorelin. No head-to-head human trial compares them. ## Ipamorelin vs tesamorelin Tesamorelin is the only approved compound in this neighborhood — a stabilized GHRH analog cleared for one narrow indication (HIV-associated lipodystrophy), with real human outcome trials behind it. Ipamorelin has none of that: no approval, a failed Phase 2 ileus trial [5], and a record that is otherwise preclinical. Tesamorelin acts on the GHRH receptor; ipamorelin on the ghrelin receptor [4]. The contrast is the point — one is an approved GHRH-side drug with human data, the other a selective GHRP-side research peptide. They are not interchangeable and have never been compared head-to-head in humans. --- A terminal read of the ipamorelin literature: bone data logged where the studies confirm it, the lone failed human trial left in plain view, no clinic behind the console and nothing here dosed or sold.